MolDX: Plasma-Based Genomic Profiling in Solid Tumors L39230 Final LCD - Effective December 26, 2022

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L39232

LCD Title: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Effective Date: December 26, 2022

Summary of LCD: This is a limited coverage policy for next-generation sequencing (NGS) assays performed on solid tumor cell-free deoxyribonucleic acid (DNA) in plasma, from here on called “liquid biopsies.”

Visit the Proposed LCDs webpage to access this LCD.

 

            Last Updated Mon, 14 Nov 2022 21:34:41 +0000